Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis.

Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D. · 2017

Read Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. by Cosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5701135.txt.

Introduction

Cosenza and co-authors report a mouse study in Scientific Reports. It tests stem cell vesicles against osteoarthritis damage. Mesenchymal stem cells protect cartilage in animal models. Most of that benefit flows through released mediators. Those mediators ride inside tiny extracellular vesicles. The team compared two vesicle types from bone marrow cells. Exosomes and microparticles were split by spinning steps. Effects were tested on arthritis-like cartilage cells.

Both vesicle types revived cartilage marker genes. They also curbed breakdown and inflammation markers. Treated cells resisted death, and immune cells calmed down. Injected into arthritic mouse joints, both protected tissue. The benefit matched whole stem cells themselves.

Catalog record

CREATORCosenza S, Ruiz M, Toupet K, Jorgensen C, Noël D.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5701135

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis By Stella Cosenza, Maxime Ruiz, Karine Toupet, Christian Jorgensen, Danièle Noël Published in: Scientific Reports DOI: 10.1038/s41598-017-15376-8 ABSTRACT Abstract Mesenchymal stem or stromal cells (MSCs) exert chondroprotective effects in preclinical models of osteoarthritis (OA). Most of their therapeutic effects are mediated via soluble mediators, which can be conveyed within extracellular vesicles (EVs). The objective of the study was to compare the respective role of exosomes (Exos) or microvesicles/microparticles (MPs) in OA. MPs and Exos were isolated from bone marrow murine BM-MSCs through differential centrifugation. Effect of MPs or Exos was evaluated on OA-like murine chondrocytes and chondroprotection was quantified by RT-qPCR. In OA-like chondrocytes, BM-MSC-derived MPs and Exos could reinduce the expression of chondrocyte markers (type II collagen, aggrecan) while inhibiting catabolic (MMP-13, ADAMTS5) and inflammatory (iNOS) markers. Exos and MPs were also shown to protect chondrocytes from apoptosis and to inhibit macrophage activation. In vivo, Exos or MPs were injected in the collagenase-induced OA (CIOA) model and histomorphometric analyses of joints were performed by µCT and confocal laser microscopy. BM-MSCs, MPs and Exos equally protected mice from joint damage. In conclusion, MPs and Exos exerted similar chondroprotective and anti-inflammatory function in vitro and protected mice from developing OA in vivo, suggesting that either Exos or MPs reproduced the main therapeutic effect of BM-MSCs. INTRODUCTION Osteoarthritis (OA) is the most prevalent rheumatic disease, characterized by cartilage degradation, sub-chondral bone sclerosis, osteophyte formation, synovial inflammation and calcification of ligaments. The main risks factors are age, obesity, genetics and joint injuries following traumas. Its prevalence is constantly increasing, making this disease among the main causes of years lived with disability1. It induces enormous public health resources devoted to the cure, prevention and amelioration of sequelae of the disease. Current treatments are only symptomatic relying on the use of antalgics and non-steroid anti-inflammatory drugs (NSAID). Because these treatments are palliative and not curative, other therapeutic strategies have to be developed. In recent years, mesenchymal stem/stromal cell (MSC)-based therapies have emerged as a novel opportunity to positively impact on the outcome of OA. We and others have shown in pre-clinical models that intra-articular injection of MSCs, either from bone marrow or adipose tissue, could protect cartilage from degeneration and at least delay OA progression2–5. MSC-based therapy for OA is also being evaluated in the clinics and encouraging results on pain and inflammation reduction have been reported6,7. Most of the therapeutic effects are attributed to the secretion of mediators with anti-inflammatory and chondroprotective functions8,9. However, some recent evidence suggests that those mediators are conveyed within extracellular vesicles (EVs) released by MSCs. EVs are a heterogeneous population of particles released by virtually all cell types and involved in cell-to-cell communication pathways. There are three main classes: exosomes or small-size vesicles, microparticles or microvesicles and apoptotic bodies. They are characterized by their size, biogenesis and expression of membrane markers. Exosomes (Exos) are generated via the endosomal compartment in multivesicular bodies and express endosomal markers (CD9, CD61, CD83, ALIX, TSG101) while microparticles (MPs) are released by cell membrane budding and express markers from the parental cell (for review, see10). The therapeutic effect of MSC-derived EVs in OA has been recently described in three studies with contradictory results. In the first one, MSC-derived Exos were shown to decrease the anabolic function of chondrocytes, except when MSCs were engineered to express miR-140-5p11. In the second one, Exos isolated from iPS-derived MSCs or synovial MSCs successfully decreased OA symptoms in vivo but Exos from iPS-derived MSCs were more efficient12. In the most recent article, a beneficial effect of embryonic stem cell-derived Exos was reported in the destabilization of the medial meniscus (DMM) model13. However, none of these studies reported the effect of other types of EVs. One objective of the present study was to characterize in vitro the functional role of either Exos or MPs isolated from bone marrow (BM-MSCs) on the function of cells from the articular environment, chondrocytes and monocytes/macrophages. The second objective was to characterize in depth the in vivo therapeutic effect of the two types of EVs in a preclinical model of OA using quantitative histomorphometric parameters of bone and cartilage tissues. MATERIALS AND METHODS Mesenchymal stem cell culture and EV production Murine BM-MSCs were isolated from bone marrow of C57BL/6 mice and previously characterized by phenotyping and trilineage differentiation potential as described in14. They were expanded in proliferative medium consisting in DMEM, 100 µg/mL penicillin/streptomycin, 2 mmol/mL glutamine and supplemented with 10% foetal calf serum (FCS). BM-MSCs were used between passages 10 and 20. For EV production, BM-MSCs were seeded in proliferative medium at 2 × 104 cells/cm² and maintained in proliferative medium for 24 h. For evaluating the chondroprotective function of EVs uniquely, TGF-β3 (10 ng/mL) was added in the proliferative medium for 24 h. Proliferative medium was then replaced by production medium consisting in DMEM, 100 µg/mL penicillin/streptomycin, 2 mmol/mL glutamine and 3% EVs-free FCS. EVs-free FCS containing medium was obtained by ultracentrifugation of DMEM plus 20% FCS at 100,000 g overnight and kept at 4 °C before dilution with DMEM for use. After 48 h, BM-MSC-conditioned medium (CM) was centrifuged at 300 g for 10 min to eliminate cells and 2,500 g for 25 min to remove debris and apoptotic bodies. For MP isolation, CM was centrifuged at 18,000 g for 1 h in polyallomer tubes; the pellet was then suspended in PBS and submitted to a second round of centrifugation. For Exos, supernatant from MP fraction was filtered on 0.22 µm porous membrane and centrifuged at 100,000 g for 2 h. Pellet was suspended in PBS and centrifuged again at 100,000 g for 2 h. Both MP and Exo pellets were suspended in 100 µL of PBS and freshly used for in vitro and in vivo functional experiments. EV characterization Production of EVs was normalized to the content in total protein as quantified by Bradford Colorimetric Assay (BCA) assay. Size distribution of EVs was determined by Nanoparticle Tracking Analysis in a NanoSight LM10-12 instrument as advised by manufacturer (Malvern) and by Dynamic Light Scattering (DLS). In vitro model of OA like chondrocytes Murine chondrocytes were isolated from 3 days old C57BL/6 mice as described in15 and, induced to express an OA-like phenotype by addition of IL-1β as described elsewhere (Ruiz et al., submitted). Briefly, IL-1β (1 ng/mL) was added to chondrocytes cultured in DMEM containing 10% FCS, 100 µg/mL penicillin/streptomycin, 2 mmol/mL glutamine. In parallel, BM-MSC-CM was prepared from BM-MSCs cultured in proliferative medium supplemented or not with 10 ng/mL TGF-β3. After 24 h, chondrocyte medium was replaced by medium containing different amounts of MPs or Exos (12.5 ng; 125 ng or 1.25 µg), BM-MSC-CM (1 mL) or BM-MSCs (105 cells) on top of a transwell membrane. Following another 24 h of incubation, chondrocytes were then recovered and processed for RT-qPCR analysis. Apoptosis induction Murine articular chondrocytes were isolated and plated in 12 wells culture plates as described above. After 5 days, confluent BM-MSCs (105 cells) adherent on a transwell membrane (0.4 µm) were added in chondrocytes-containing wells for 24 h. Afterwards, all media in wells containing chondrocytes alone or chondrocytes/BM-MSCs cocultures were replaced by fresh medium

Read the complete text